Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Travoprost
Drug ID BADD_D02265
Description Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure [FDA Label]. It is a synthetic prostaglandin F2alpha analog [FDA Label]. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension [L5155]. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride [L5155]. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146, L5152].
Indications and Usage Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Marketing Status Prescription; Discontinued
ATC Code S01EE04
DrugBank ID DB00287
KEGG ID D01964
MeSH ID D000069557
PubChem ID 5282226
TTD Drug ID D09CZA
NDC Product Code 54893-0020; 40016-006; 0078-0946; 82231-114; 45542-1162; 38779-3063; 64181-0028; 63629-8839; 65035-131; 65129-1207; 61556-040; 0781-6185; 24002-0022; 68245-0003; 63190-0350; 60505-0593; 63629-8840; 55359-540
Synonyms Travoprost | Travatan Z | Z, Travatan | Travatan | (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester | AL-6221 | AL 6221 | AL6221
Chemical Information
Molecular Formula C26H35F3O6
CAS Registry Number 157283-68-6
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.001187%Not Available
Abdominal pain07.01.05.002--
Abnormal sensation in eye06.01.01.001--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Asthenopia06.01.01.002--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.0020.000791%
Back pain15.03.04.005--
Blepharitis23.03.04.012; 06.04.04.0010.001187%Not Available
Blindness06.02.02.001; 17.17.01.0030.001979%Not Available
Blood pressure diastolic decreased13.14.03.003--Not Available
Blood pressure increased13.14.03.0050.001583%Not Available
Blood pressure systolic increased13.14.03.006--Not Available
Bone disorder15.02.04.004--Not Available
Bradycardia02.03.02.002--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Burning sensation17.02.06.001; 08.01.09.0290.000791%Not Available
Cataract06.06.01.0010.000791%
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.001583%Not Available
Choroidal detachment12.01.04.006; 06.09.01.0030.001187%Not Available
Confusional state17.02.03.005; 19.13.01.0010.001187%
Conjunctival follicles06.06.02.002--Not Available
Conjunctival haemorrhage06.07.01.001; 24.07.05.001--Not Available
Conjunctival oedema06.04.01.001--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages